Clinical trial
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the…
NCT00226460 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00226460 |
|---|---|
| Title | Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | Diacrin/Genzyme Corporation LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Fetal porcine cells, Neurocell-PD |
| Start date | Aug 1, 1997 |
| Completion | Jan 1, 2001 |
| First posted | Sep 27, 2005 |
| Last update posted | Mar 18, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: